No intention of disturbing peace; I was not well: BJP MP on arson threat

New Delhi, Jan 17: The Supreme Court on Friday closed the monitoring of the killing of rationalist M M Kalburgi in 2015 in Dharwad.

A bench of Justices R F Nariman and S Ravindra Bhat noted that the charge sheet has already been filed and the matter was assigned to the sessions court. The court, however, noted two accused had absconded and could not be arrested till date, according to reports.

Senior advocate Devadatt Kamat, appearing for the Karnataka government, submitted that the High Court had also stopped monitoring of the matter.

The top court had in early last year directed that the Karnataka High Court's Dharwad bench to monitor the probe. The Karnataka police SIT, which investigated Gauri Lankesh case and filed the charge sheet, was allowed to take over the Kalburgi case.

Umadevi, in her 2017 plea, drew a parallel between Kalburgi's murder and killings of Narendra Dabholkar and Comrade Govind Pansare in Maharashtra and sought an SIT probe by a retired Supreme Court or a High Court judge. She urged the top court to monitor the probe till it reached its logical conclusion as there was no progress in the investigation conducted so far by the Karnataka police.

The court had earlier sought to know if there was a "common thread" in murder cases of Communist leader Pansare and rationalist Dabholkar in Maharashtra, and Kannada writer Kalburgi and journalist-activist Gauri Lankesh in Karnataka.

Bengaluru, Jun 6: Karnataka registered 378 Covid-19 cases in the past 24 hours, breaching the 5,000-mark to settle at 5,213, said an official, here on Saturday. "New cases reported from Friday 5 p.m. to Saturday 6 p.m. is 378," said a health official.

Of the new cases, 333 are local returnees, comprising 88 per cent of the new infections. Returnees from Maharashtra accounted for 99 per cent new cases at 329.

Majority infections in Karnataka nowadays are returnees, mostly from the state''s northern neighbour. Only 27 new infections were contacts of earlier cases.

On Saturday, cases spiked in Udupi, Kalaburagi, Yadgir, Bengaluru Urban, Belagavi, Vijayapura, Davangere and Dakshina Kannada.

Udupi witnessed the highest number of cases (121), followed by Yadgir (103), Kalaburagi (69), Dakshina Kannada (24), Bengaluru Urban (18), Vijayapura and Davangere (6 each), Belagavi (5), Gadag (4), Mandya, Hassan, Dharwad and Haveri (3 each), Raichur, Chikkaballapura and Uttara Kannada (2 each) and Bidar, Tumkur, Kolar and Koppal (1 each).

Among the new cases, three patients from Bengaluru Urban are suffering from Influenza Like Illness (ILI) and another from Severe Acute Respiratory Infection (SARI).

There were seven cases with international travel history to United Arab Emirates (UAE) and one to Turkey.

Meanwhile, 280 people were discharged in the past 24 hours and two persons succumbed to the virus, one from Bidar and another from Vijayapura. Of all the cases, 3,184 are active, 1,968 discharged, 59 dead and 11 in the ICU.

In the past 24 hours, Karnataka tested 11,862 people, of which 11,431 reports returned negative. In total, 3.72 lakh samples have been tested so far, of which 3.61 lakh have returned negative.

Currently, Udupi is leading the state''s Covid-19 burden with 785 active cases, followed by Kalaburagi (448), Yadgir (407), Raichur (320) and Mandya (163) among others.

Bengaluru Urban has accounted for 13 deaths, followed by Kalaburagi (7), Bidar, Vijayapura, Davangere and Dakshina Kannada (6 each) and Chikkaballapura (3 each), among others.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.